全球心脏生物标志物检测市场 – 行业趋势及 2030 年预测

心脏生物标志物检测市场分析和规模

据世界卫生组织统计，印度约有 477 万人患有心血管疾病，其中约 3.1% 的人口因肥胖而患上心绞痛。为了减轻疾病负担，印度政府正在推出一系列举措，以提高农村地区的人们的认识。多家政府和私人医疗机构及诊断实验室正在实施心脏生物标志物诊断检测试剂盒，以满足日益增长的患者群体的需求。

Data Bridge Market Research 分析，心脏生物标志物检测市场在 2022 年的规模为 120.9897 亿美元，预计到 2030 年将达到 284.9113 亿美元，在 2023 年至 2030 年的预测期内复合年增长率为 11.30%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

心脏生物标志物检测市场范围和细分  

Market Definition

Cardiac markers, also known as cardiac biomarkers, are released into the bloodstream when the heart is stressed or its muscles are damaged. These markers include enzymes, hormones, and proteins such as cardiac troponins, creatine kinase (CK), ischemia-modified albumin (IMA), and myoglobin. The measurement and testing of these markers can aid in the diagnosis of heart conditions such as cardiac ischemia and acute coronary syndrome (ACS). At the moment, the triage and diagnostic systems used to determine the risk of these conditions are based on electrocardiograms (ECGs) and clinical history.

Cardiac Biomarkers Testing Market Dynamics

Drivers

• Rising prevalence of cardiovascular diseases

With the rising prevalence of cardiovascular diseases, the demand for these diagnostic test kits is expected to rise in the coming years. According to WHO, the mortality rate from heart failure is rising, accounting for more than 15.60% of total deaths in the country. To slow the rate of increase, the government and healthcare organizations are taking preventive measures to educate the public about the benefits of these test kits. As a result of the above-mentioned factors, the market for cardiac biomarkers testing is expected to grow during the forecast period.

• Rising prevalence of coronary heart disease

The rising prevalence of coronary heart disease has increased the number of cases of angina pectoris/chest pain, particularly among the elderly. According to the World Health Organization, nearly 17 million people died from cardiovascular diseases in 2019. Around 20% of those were diagnosed with angina pectoris. In addition, as millennials consume unhealthier foods, the prevalence of angina pectoris has increased. As a result, demand for cardiac biomarkers testing is expected to rise in order to meet the growing patient population.

Opportunities

• Government Initiatives

In the outbreak of COVID-19, governments around the world have launched a number of initiatives to improve healthcare infrastructure. Increasing healthcare spending, particularly in emerging economies such as India, South Korea, and Japan, has increased demand for advanced medical devices such as cardiac biomarkers diagnostic test kits. According to the India Brand Equity Foundation (IBEF), the Government of India approved the continuation of the "National Health Mission" in the Union Budget for 2021-22 with a budget of US$ 5.10 billion. Under this policy, the government will provide advanced medical devices in rural areas for cardiology, neurology, and other diseases in order to reduce global mortality. A slew of such initiatives around the world are expected to create market growth opportunities.

Restraints/Challenges

• Side effects associated with cardiac biomarkers

Rising side effects such as skeletal muscle injury and limited specificity in some cases will obstruct market growth and will further challenge the growth of the cardiac biomarkers testing market during the forecast period.

This cardiac biomarkers testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the cardiac biomarkers testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Roche announced the launch of five new intended uses for two key cardiac biomarkers using Elecsys technology high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These biomarkers aid in managing cardiovascular disease and can assist clinicians in diagnosing heart attacks and managing heart failure.
• In 2021, Baxter International Inc., a global leader in acute care, will collaborate with bioMérieux, a global leader in in vitro diagnostics, to launch the CE marking of the NEPHROCLEARTM CCL14 Test.

Global Cardiac Biomarkers Testing Market Scope

The cardiac biomarkers testing market is segmented on the basis of type, application and location of testing. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Myocardial muscle Creatine Kinase (CK-MB)
• Troponins (T and I)
• Myoglobin, Brain Natriuretic Peptide (BNPs)
• NT-proBNP
• Ischemia Modified Albumin (IMA)

 Application

• 心肌梗塞
• 充血性心力衰竭
• 急性冠状动脉综合征
• 动脉粥样硬化

检测地点

• 护理点
• 实验室

心脏生物标志物检测市场区域分析/见解

对心脏生物标志物检测市场进行了分析，并按上述国家、检测类型、应用和地点提供了市场规模洞察和趋势。

心脏生物标志物检测市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区 (APAC) 的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

由于心脏检测需求增加、心血管疾病患病率高以及对心脏诊断解决方案认识的提高，北美在心脏生物标志物检测市场占据主导地位。

由于亚太地区现代化程度不断提高、可支配收入不断增加以及负担能力不断提高，预计该地区将在 2023 年至 2030 年的预测期内实现最高增长率。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。

医疗保健基础设施增长安装基础和新技术渗透

心脏生物标志物检测市场还为您提供了每个国家/地区资本设备医疗保健支出增长、心脏生物标志物检测市场不同类型产品的安装基数、使用生命线曲线的技术的影响以及医疗保健监管情景的变化及其对心脏生物标志物检测市场的影响的详细市场分析。数据涵盖 2011-2021 年的历史时期。

竞争格局和心脏生物标志物检测市场份额分析

心脏生物标志物检测市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对心脏生物标志物检测市场的关注有关。

心脏生物标志物检测市场的一些主要参与者包括：

• F. Hoffmann-La Roche Ltd.（瑞士）
• 赛默飞世尔科技公司（美国）
• 雅培（美国）
• QIAGEN（德国）
• PerkinElmer, Inc.（美国）
• 默克集团（德国）
• Bio-Rad Laboratories, Inc.（美国）
• Enzo Biochem, Inc.（美国）
• Charles River Laboratories（美国）
• Eurofins Scientific（卢森堡）
• 安捷伦科技公司（美国）
• 布鲁克 (美国)
• 西门子（德国）
• Epigenomics AG（德国）
• 通用电气（美国）

SKU-57144